VTGN

VistaGen Therapeutics Inc

VTGN, USA

Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase II clinical trial to treat major depressive disorder. It also develops PH80, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase II clinical trial for the treatment of vasomotor symptoms, including hot flashes due to menopause, premenstrual dysphoric disorder, and other women's health disorders; PH15, an investigational pherine nasal spray, which is in Phase II clinical trial for the treatment to improve cognitive impairment caused by mental fatigue and potentially other disorders; PH284, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase II clinical trial to treat loss of appetite associated with chronic disorders, such as cancer or heart disease, as well as cachexia; and AV-101, an oral prodrug that targets N-methyl-D-aspartate receptor in the brain for treating depression and neurological disorders. In addition, the company's clinical-stage pipeline consists of intranasal product candidates comprising pherines. It has a license and collaboration agreement with AffaMed Therapeutics, Inc. to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders. Vistagen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

https://www.vistagen.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
VTGN
stock
VTGN

VistaGen Therapeutics (NASDAQ:VTGN) Share Price Crosses Above 50-Day Moving Average - Should You Sell? MarketBeat

Read more →
VTGN
stock
VTGN

Would You Still Hold Vistagen Therapeutics Stock If It Fell 30%? Trefis

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$14.5

Analyst Picks

Strong Buy

3

Buy

1

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

High

2.29

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-29.27 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-23.99 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-5,356.20 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.22

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 56.15% of the total shares of VistaGen Therapeutics Inc

1.

TCG Crossover Management, LLC

(8.7241%)

since

2025/06/30

2.

StemPoint Capital LP

(7.8658%)

since

2025/06/30

3.

Nantahala Capital Management, LLC

(6.4487%)

since

2025/06/30

4.

Vanguard Group Inc

(5.7354%)

since

2025/06/30

5.

COMMODORE CAPITAL LP

(5.1336%)

since

2025/06/30

6.

Vanguard Total Stock Mkt Idx Inv

(3.792%)

since

2025/07/31

7.

JPMorgan Chase & Co

(2.4408%)

since

2025/06/30

8.

Ikarian Capital, LLC

(1.9612%)

since

2025/06/30

9.

Sphera Funds Management Ltd.

(1.46%)

since

2025/06/30

10.

ADAR1 Capital Management LLC

(1.3714%)

since

2025/06/30

11.

BlackRock Inc

(1.3588%)

since

2025/06/30

12.

Diadema Partners LP

(1.3165%)

since

2025/06/30

13.

Vanguard Institutional Extnd Mkt Idx Tr

(1.0996%)

since

2025/07/31

14.

Geode Capital Management, LLC

(0.8895%)

since

2025/06/30

15.

Almitas Capital LLC

(0.852%)

since

2025/06/30

16.

AdvisorShares Psychedelics ETF

(0.7106%)

since

2025/08/29

17.

AdvisorShares Investments, LLC

(0.662%)

since

2025/06/30

18.

BOOTHBAY FUND MANAGEMENT, LLC

(0.5797%)

since

2025/06/30

19.

BML Capital Management LLC

(0.4889%)

since

2025/06/30

20.

Fidelity Extended Market Index

(0.4193%)

since

2025/07/31

21.

Susquehanna International Group, LLP

(0.376%)

since

2025/06/30

22.

State Street Corp

(0.3157%)

since

2025/06/30

23.

Jane Street Group LLC

(0.3098%)

since

2025/06/30

24.

Two Sigma Investments LLC

(0.2916%)

since

2025/06/30

25.

iShares Micro-Cap ETF

(0.2102%)

since

2025/08/31

26.

Extended Equity Market Fund K

(0.1957%)

since

2025/06/30

27.

Fidelity Total Market Index

(0.1544%)

since

2025/07/31

28.

Fidelity Series Total Market Index

(0.1097%)

since

2025/07/31

29.

Avantis US Small Cap Equity ETF

(0.1018%)

since

2025/08/30

30.

Spartan Extended Market Index Pool F

(0.101%)

since

2025/07/31

31.

Vifag 2002 SICAV

(0.0978%)

since

2025/07/31

32.

NT Ext Equity Mkt Idx Fd - L

(0.0888%)

since

2025/06/30

33.

Northern Trust Extended Eq Market Idx

(0.0888%)

since

2025/06/30

34.

Schwab Total Stock Market Index

(0.076%)

since

2025/07/31

35.

NT Ext Equity Mkt Idx Fd - NL

(0.0656%)

since

2025/06/30

36.

Spartan Total Market Index Pool G

(0.0644%)

since

2025/07/31

37.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0509%)

since

2025/06/30

38.

DFA US Micro Cap I

(0.0494%)

since

2025/07/31

39.

Vanguard Instl Ttl Stck Mkt Idx Tr

(0.0472%)

since

2024/12/31

40.

Dimensional US Targeted Value ETF

(0.0404%)

since

2025/08/29

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.54

EPS Estimate

-0.53

EPS Difference

-0.01

Surprise Percent

-1.8868%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(4)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.8)
GARP
Not Attractive for GARP(3)
Growth
Weak Growth Prospect(1.5)
Momentum
Moderate Momentum(5.5)
Net Net
Not Undervalued (Net-Net)(3)
Quality
Low Quality Business(2.5)
Value
Fair Value(4)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.